Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CVKD Cadrenal Therapeutics
2.160-0.090-4.00%
Close
02/07 16:00 ET
2.200+0.040+1.85%
Post Mkt Price 02/07 17:38 ET
High
2.304
Open
2.200
Turnover
154.02K
Low
2.100
Pre Close
2.250
Volume
70.80K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference
Cadrenal Therapeutics Announces Formation of Scientific Advisory Board
Stocks That Hit 52-Week Lows On Monday
 On Monday, 13 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Bridger Aerospace Gr (NASDAQ:BAER) was the largest company by market cap to set a new 52-week low.The s
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering
PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug
Stocks That Hit 52-Week Lows On Tuesday
 During Tuesday, 17 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was CVS Health (NYSE:CVS).The smalles
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Baudax Bio, Inc. (NASDAQ:BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in p
Cadrenal Therapeutics Hit Lowest Point Since Friday IPO, Down 21%
By Chris Wack Cadrenal Therapeutics Inc. shares hit their lowest point since their initial public offering Friday, dropping 21% to $3.11. The stock climbed as high as $5.81 Monday after the company
Baudax, BioAffinity Top Healthcare Gainers; Altamira, Tenax Lead Losers' Pack
Cadrenal Shares Rise 7% After Tecarfarin's FDA Fast-Track Designation
By Chris Wack Cadrenal Therapeutics Inc. shares were up 7% to $4.42 Monday after the company said the U.S. Food and Drug Administration granted a fast-track designation to tecarfarin, its anti-blood
What's Going On With Cadrenal Therapeutics Stock Today
The FDA has granted a Fast Track designation to Cadrenal Therapeutics Inc's (NASDAQ:CVKD) tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardia
Company Overview
More
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham on January 25, 2022 and is headquartered in Ponte Vedra, FL.
CEO： Mr. Quang Pham
Market： NASDAQ
Listing Date： 01/20/2023
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet